Parkinson Therapy Breakthrough Fails to Lift Bayer’s Stock
Published on 09/25/2025 at 17:09 | Redaktion boerse-global.de
Bayer shares experienced a decline on Wednesday, despite the company announcing a significant advancement in its Parkinson’s disease treatment program. The pharmaceutical and agricultural giant has dosed the first patient in a pivotal Phase III clinical trial for its promising cell therapy, Bemdaneprocel. This milestone, which follows a successful Phase I study, could substantially accelerate the path to market for this potential breakthrough treatment. A separate Phase II trial for an additional Parkinson’s gene therapy is also launching in Europe.
The lack of a positive market reaction highlights a clear disconnect between long-term research potential and immediate financial concerns. Investors appear to be focusing on pressing issues rather than future prospects. The therapy itself represents a novel approach, aiming... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
